Atopic Dermatitis

In this edition, lack of sunless tanner education may cause confusion; intralesional HPV vaccine may clear recalcitrant warts; Ilumetri improves well-being of patients with plaque psoriasis and more.

CHICAGO — By protecting the skin barrier against atopic dermatitis, physicians may prevent food allergy as well, according to a presentation at the Global Food Allergy Prevention Summit.

Alphyn Biologics presented interim data from the second cohort of its phase 2a clinical trial program of AB-101a for the treatment of atopic dermatitis, according to a presentation at the Society for Pediatric Dermatology annual meeting.

Once-daily crisaborole ointment 2% may be an effective and well-tolerated long-term maintenance therapy for pediatric and adult patients with mild to moderate atopic dermatitis, according to a study.

Alphyn Biologics announced new data from its phase 2a clinical trial evaluating topical AB-101a for the treatment of mild to moderate atopic dermatitis in patients aged as young as 2 years, according to a company release.

CHICAGO — Allergists treating atopic dermatitis might consider focusing on the skin microbiome to improve outcomes, according to a presenter at the Global Food Allergy Prevention Summit.

Patients taking lebrikizumab for the treatment of moderate to severe atopic dermatitis maintained similar responses regardless of dose frequency, according to results presented at 25th World Congress of Dermatology in Singapore.

In this Healio video exclusive, George Martin, MD, discusses highlights from Maui Derm NP+PA, including the use of oral and topical JAK inhibitors to treat atopic dermatitis.

Patients with rosacea, alopecia areata, psoriasis or atopic dermatitis all face an elevated risk for cardiovascular disease, according to a study.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion of Adtralza for injection in a new single-dose 2 ml pre-filled pen, according to a press release.